A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

In this edition of InnovationRx, medical debts will be erased from credit histories, this farm is doubling down on raw milk ...

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetrationEnrolling ...

Dame Esther responded after a columnist tried to use her own cancer experience as an argument against assisted dying.

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...

Cullinan Therapeutics’ strong financial position funds growth into 2028. Find out why CGEM stock presents a compelling buy ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...

Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung cancer.

Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...